Ranbaxy Lawsuit
- All
- News
-
Sun Pharma Withdraws Suit Filed by Ranbaxy Against USFDA
Drug major Sun Pharmaceutical has withdrawn its appeal in the lawsuit filed by Ranbaxy against the US health regulator challenging FDA's decision to revoke approvals for generic versions of Nexium and Valcyte.
-
Sun Pharma Falls After Ranbaxy Gets Slapped With Lawsuit
Sun Pharma is India's largest drugmaker.
-
US Class Action Asserts Ranbaxy Manipulated FDA Rules
Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. It was filed by US retailer Meijer Inc on Tuesday in the US District Court in Massachusetts.
-
US Court Denies Ranbaxy's Bid to Block Launch of Rival Generics
Ranbaxy had filed a lawsuit against the US Food and Drug Administration last week for revoking tentative approvals it gave the company to make generics of Valcyte and Nexium.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Ranbaxy to pay $500 million in US lawsuit settlement
The settlement is its largest-ever with a generic drugmaker over drug safety, according to the US government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Relief to Ranbaxy: US court rejects Mylan's lawsuit
A US court has dismissed a lawsuit filed by Mylan Pharmaceuticals against health regulator USFDA seeking action against Ranbaxy Laboratories' application to sell the generic version of cholesterol drug Lipitor. US-based Mylan had moved the court, mainly to ensure that it would be able to market Lipitor's generic version. The District Court ...
-
Sun Pharma Withdraws Suit Filed by Ranbaxy Against USFDA
Drug major Sun Pharmaceutical has withdrawn its appeal in the lawsuit filed by Ranbaxy against the US health regulator challenging FDA's decision to revoke approvals for generic versions of Nexium and Valcyte.
-
Sun Pharma Falls After Ranbaxy Gets Slapped With Lawsuit
Sun Pharma is India's largest drugmaker.
-
US Class Action Asserts Ranbaxy Manipulated FDA Rules
Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. It was filed by US retailer Meijer Inc on Tuesday in the US District Court in Massachusetts.
-
US Court Denies Ranbaxy's Bid to Block Launch of Rival Generics
Ranbaxy had filed a lawsuit against the US Food and Drug Administration last week for revoking tentative approvals it gave the company to make generics of Valcyte and Nexium.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Ranbaxy to pay $500 million in US lawsuit settlement
The settlement is its largest-ever with a generic drugmaker over drug safety, according to the US government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Relief to Ranbaxy: US court rejects Mylan's lawsuit
A US court has dismissed a lawsuit filed by Mylan Pharmaceuticals against health regulator USFDA seeking action against Ranbaxy Laboratories' application to sell the generic version of cholesterol drug Lipitor. US-based Mylan had moved the court, mainly to ensure that it would be able to market Lipitor's generic version. The District Court ...
